Shao Xinyi, Pan Xingyu, Chen Yangmei, Zhu Yan, Chen Shuang, Chen Jin
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
J Asthma Allergy. 2024 Dec 3;17:1259-1263. doi: 10.2147/JAA.S492614. eCollection 2024.
Atopic dermatitis (AD) may sometimes be comorbid with vitiligo. However, these therapeutic agents are often slow acting and lead to various adverse effects, resulting in poor patient compliance. This report describes a 65-year-old male patient with refractory moderate-to-severe atopic dermatitis (AD) and generalized vitiligo. The patient was treated with repeated antihistamine and dupilumab injections; however, erythema and pruritus did not improve. Consequently, oral abrocitinib was administered to treat AD and vitiligo, and the patient's generalized erythema, papules, and pruritus ameliorated with the repigmentation of vitiligo lesions. This case provided evidence of the efficacy and safety of oral abrocitinib for patients with concurrent refractory AD and vitiligo.
特应性皮炎（AD）有时可能与白癜风合并存在。然而，这些治疗药物往往起效缓慢，并会导致各种不良反应，从而导致患者依从性较差。本报告描述了一名65岁男性患者，患有难治性中度至重度特应性皮炎（AD）和泛发性白癜风。该患者接受了反复的抗组胺药和度普利尤单抗注射治疗；然而，红斑和瘙痒并未改善。因此，给予口服阿布昔替尼治疗AD和白癜风，患者的全身性红斑、丘疹和瘙痒症状得到改善，白癜风皮损也出现了色素再生。该病例为口服阿布昔替尼治疗同时患有难治性AD和白癜风的患者的有效性和安全性提供了证据。
